Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast
Beyond Air (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company specializing in nitric oxide (NO) treatments, has announced its upcoming fiscal year 2025 financial results conference call. The company will report its fiscal fourth quarter and full year results ended March 31, 2025 on Tuesday, June 17, 2025.
The management team will host a conference call and webcast at 4:30 PM Eastern Time. Investors can access the call through domestic (1-877-407-0784) or international (1-201-689-8560) lines using conference ID 13753945. A webcast will be available through the company's website, with a replay accessible one hour after the call.
Beyond Air (NASDAQ: XAIR), azienda nel settore dei dispositivi medici e biofarmaceutici specializzata in trattamenti a base di ossido nitrico (NO), ha annunciato la conferenza telefonica per la presentazione dei risultati finanziari del prossimo anno fiscale 2025. La società comunicherà i risultati del quarto trimestre fiscale e dell'intero anno conclusi al 31 marzo 2025 il martedì 17 giugno 2025.
Il team di gestione terrà una conferenza telefonica e una webcast alle 16:30 ora della costa orientale degli Stati Uniti. Gli investitori potranno partecipare chiamando le linee nazionali (1-877-407-0784) o internazionali (1-201-689-8560) utilizzando l'ID conferenza 13753945. La webcast sarà disponibile sul sito web della società, con la possibilità di riascoltare la registrazione a partire da un'ora dopo la chiamata.
Beyond Air (NASDAQ: XAIR), una empresa en etapa comercial dedicada a dispositivos médicos y biofarmacéuticos especializada en tratamientos con óxido nítrico (NO), ha anunciado su próxima llamada de conferencia para los resultados financieros del año fiscal 2025. La compañía reportará sus resultados del cuarto trimestre fiscal y del año completo finalizados el 31 de marzo de 2025 el martes 17 de junio de 2025.
El equipo directivo realizará una llamada de conferencia y una transmisión en vivo a las 4:30 PM hora del Este. Los inversores pueden acceder a la llamada a través de líneas nacionales (1-877-407-0784) o internacionales (1-201-689-8560) usando el ID de conferencia 13753945. La transmisión estará disponible en el sitio web de la empresa, con una repetición accesible una hora después de la llamada.
Beyond Air (NASDAQ: XAIR)는 상업 단계의 의료기기 및 생명공학 회사로, 일산화질소(NO) 치료제를 전문으로 하며, 다가오는 2025 회계연도 재무 실적 컨퍼런스 콜을 발표했습니다. 회사는 2025년 3월 31일 종료된 4분기 및 전체 회계연도 실적을 2025년 6월 17일 화요일에 발표할 예정입니다.
경영진은 동부 표준시 오후 4시 30분에 컨퍼런스 콜과 웹캐스트를 진행합니다. 투자자들은 국내 전화(1-877-407-0784) 또는 국제 전화(1-201-689-8560)를 통해 회의 ID 13753945를 사용하여 접속할 수 있습니다. 웹캐스트는 회사 웹사이트에서 제공되며, 콜 종료 1시간 후부터 재청취가 가능합니다.
Beyond Air (NASDAQ : XAIR), une entreprise commerciale spécialisée dans les dispositifs médicaux et les produits biopharmaceutiques axée sur les traitements à base d'oxyde nitrique (NO), a annoncé sa prochaine conférence téléphonique sur les résultats financiers de l'exercice 2025. La société publiera ses résultats du quatrième trimestre fiscal et de l'année complète clôturés au 31 mars 2025 le mardi 17 juin 2025.
L'équipe de direction animera une conférence téléphonique et une webdiffusion à 16h30, heure de l'Est. Les investisseurs pourront accéder à l'appel via des lignes nationales (1-877-407-0784) ou internationales (1-201-689-8560) en utilisant l'ID de conférence 13753945. Une webdiffusion sera disponible sur le site internet de la société, avec un replay accessible une heure après l'appel.
Beyond Air (NASDAQ: XAIR), ein Unternehmen im Bereich medizinischer Geräte und Biopharmazeutika mit Schwerpunkt auf Stickstoffmonoxid (NO)-Behandlungen, hat seine bevorstehende Telefonkonferenz zu den Finanzergebnissen für das Geschäftsjahr 2025 angekündigt. Das Unternehmen wird seine Ergebnisse für das vierte Quartal und das Gesamtjahr zum 31. März 2025 am Dienstag, den 17. Juni 2025 bekanntgeben.
Das Management-Team wird eine Telefonkonferenz und einen Webcast um 16:30 Uhr Eastern Time abhalten. Investoren können über nationale (1-877-407-0784) oder internationale (1-201-689-8560) Leitungen unter Verwendung der Konferenz-ID 13753945 teilnehmen. Ein Webcast wird auf der Website des Unternehmens verfügbar sein, mit einer Wiederholung, die eine Stunde nach der Telefonkonferenz abrufbar ist.
- None.
- None.
GARDEN CITY, N.Y., May 20, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its fiscal fourth quarter and full year ended March 31, 2025 on Tuesday, June 17, 2025. The Company's management team is scheduled to host a conference call and webcast at 4:30 pm Eastern Time the same day.
| Conference Call & Webcast | |
| Tuesday, June 17th @ 4:30 PM ET | |
| Domestic: | 1-877-407-0784 |
| International: | 1-201-689-8560 |
| Conference ID: | 13753945 |
Webcast: A webcast of the live conference call can be accessed by visiting the Events section of the Company’s website (click here) or directly (click here). An online replay will be available on the Company’s website or via the direct link an hour after the call.
About Beyond Air®, Inc.
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit® PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM).
The Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.
Forward Looking Statements
This press release contains “forward-looking statements” concerning the potential safety and efficacy of inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings, business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “appears,” “expects,” “plans,” “anticipates,” “believes” “expects,” “intends,” “looks,” “projects,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including those related to the completion of the offering, risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for our product candidates; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; the ability to fund and the results of further pre-clinical studies and clinical trials of our product candidates; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the “Risk Factors” section of Beyond Air’s most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air’s website. Beyond Air and Beyond Cancer undertake no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law.
CONTACTS:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com
(212) 915-2577
FAQ
When will Beyond Air (XAIR) report its fiscal year 2025 earnings?
How can I access Beyond Air's (XAIR) Q4 2025 earnings call?
What period will Beyond Air's (XAIR) financial results cover?
Will there be a replay available for Beyond Air's (XAIR) Q4 2025 earnings call?
